Skip to main content

Table 4 Vital signs and most frequent treatment adverse events

From: Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial

 GXST
(n = 143)
Placebo (n = 144)Total (n = 287)
Vital signs
 HR (beats/min)71.2 ± 9.369.6 ± 8.970.2 ± 9.0
 SBP (mmHg)127.5 ± 9.3127.5 ± 7.9127.5 ± 8.5
 DBP (mmHg)80.9 ± 6.380.7 ± 6.580.9 ± 6.3
Adverse events
 Fever0 (0.0%)1 (0.7%)1 (0.3%)
 Hypertension0 (0.0%)1 (0.7%)1 (0.3%)
 Palpitation0 (0.0%)1 (0.7%)1 (0.3%)
 Urinary tract infection1 (0.7%)0 (0.0%)1 (0.3%)
 Upper respiratory tract infection1 (0.7%)0 (0.0%)1 (0.3%)
 Gastrointestinal discomfort5 (3.5%)0 (0.0%)5 (1.7%)
 Total7 (4.9%)3 (2.1%)10 (3.5%)
  1. Each value represents the mean ± SD or the number (%)
  2. GXST, Guanxinshutong capsule